rapid
emerg
subsequ
spread
novel
influenza
viru
prompt
world
health
organ
declar
first
pandem
st
centuri
highlight
threat
influenza
public
health
healthcar
system
widespread
resist
class
influenza
antivir
adamantan
neuraminidas
inhibitor
occur
pandem
season
virus
render
drug
margin
util
treatment
modal
worldwid
virtual
season
strain
resist
adamantan
rimantadin
amantadin
major
season
strain
resist
oseltamivir
wide
prescrib
neuraminidas
inhibitor
nai
address
need
effect
therapi
evalu
vitro
activ
tripl
combin
antivir
drug
tcad
regimen
compos
drug
differ
mechan
action
drugresist
season
influenza
virus
amantadin
ribavirin
oseltamivir
alon
combin
test
amantadineand
oseltamivirresist
influenza
virus
use
vitro
infect
model
mdck
cell
data
show
tripl
combin
highli
synergist
drugresist
virus
synergi
tripl
combin
significantli
greater
synergi
doubl
combin
test
includ
combin
two
nai
surprisingli
amantadin
oseltamivir
contribut
antivir
activ
tcad
regimen
amantadineand
oseltamivirresist
virus
respect
concentr
activ
singl
agent
concentr
clinic
achiev
data
demonstr
tcad
regimen
compos
amantadin
ribavirin
oseltamivir
highli
synergist
resist
virus
includ
tcad
regimen
overcom
baselin
drug
resist
class
approv
influenza
antivir
thu
may
repres
highli
activ
antivir
therapi
season
pandem
influenza
global
influenza
virus
caus
substanti
morbid
mortal
human
econom
disloc
afflict
nation
year
unit
state
season
influenza
viru
infect
result
estim
death
hospit
antivir
drug
import
mean
mitig
impact
yearli
influenza
epidem
potenti
pandem
current
two
class
antivir
drug
approv
prevent
treatment
influenza
infect
channel
inhibitor
aminoadamantan
amantadin
rimantadin
neuraminidas
inhibitor
nai
oseltamivir
zanamivir
howev
preval
drugresist
strain
report
class
antivir
drug
season
influenza
could
undermin
clinic
benefit
util
monotherapi
inde
center
diseas
control
prevent
cdc
report
season
viru
isol
test
resist
adamantan
season
virus
test
resist
oseltamivir
april
novel
viru
swineorigin
capabl
humantohuman
transmiss
like
emerg
mexico
first
isol
patient
enrol
two
separ
surveil
activ
southern
california
emerg
spread
countri
led
us
offici
world
health
organ
declar
public
health
emerg
june
rais
influenza
pandem
alert
phase
phase
offici
declar
pandem
earli
publish
result
cdc
show
bear
amantadineresist
associ
mutat
ion
channel
remain
suscept
oseltamivir
zanamivir
recent
howev
cdc
report
ten
isol
test
unit
state
found
resist
oseltamivir
rais
concern
dualli
resist
virus
may
becom
preval
earlier
studi
explor
vitro
antivir
activ
synergi
singl
doubl
tripl
combin
amantadin
ribavirin
oseltamivir
panel
influenza
virus
suscept
drug
hypothesi
tripl
combin
antivir
drug
tcad
regimen
compos
drug
differ
mechan
action
act
differ
stage
viral
life
cycl
could
result
synergist
antivir
activ
result
show
drug
inde
act
synergist
tripl
combin
show
significantli
greater
synergi
doubl
combin
evalu
furthermor
found
synergi
tcad
regimen
maintain
across
multipl
season
avian
influenza
strain
includ
three
major
subtyp
avian
current
caus
signific
morbid
mortal
human
studi
sought
evalu
activ
synergi
tcad
regimen
influenza
virus
resist
amantadin
oseltamivir
data
show
amantadineresist
virus
season
oseltamivirresist
season
virus
tcad
regimen
strongli
synergist
synergi
tcad
regimen
greater
synergi
doubl
combin
surprisingli
found
amantadin
oseltamivir
contribut
synergi
tcad
regimen
concentr
activ
singl
agent
concentr
clinic
achiev
find
highlight
util
tcad
regimen
potenti
approach
address
current
limit
antivir
potenc
drug
resist
viabl
broadspectrum
therapeut
option
seriou
influenza
viru
infect
oseltamivir
carboxyl
activ
metabolit
oseltamivir
obtain
charnwood
molecular
loughborough
uk
synthesi
via
nbocprotect
acid
oseltamivir
phosphat
amantadin
obtain
moeh
catalana
barcelona
spain
ribavirin
rimantadin
purchas
sigmaaldrich
st
loui
mo
peramivir
obtain
jubil
chemsi
ltd
uttar
pradesh
india
free
base
nboc
synthesi
puriti
confirm
use
nmr
chiral
hplc
zanamivir
obtain
haorui
pharmachem
inc
edison
nj
cell
passag
minim
essenti
medium
contain
fetal
bovin
serum
hyclon
laboratori
logan
ut
antivir
evalu
serum
remov
medium
supplement
gentamicin
mgml
porcin
trypsin
unitsml
edta
mgml
obtain
singl
agent
concentrationrespons
curv
individu
drug
ad
mdck
cell
micropl
cellswel
use
three
well
concentr
use
compound
ad
follow
concentr
oseltamivir
carboxyl
zanamivir
peramivir
mgml
amantadin
rimantadin
ribavirin
mgml
untreat
well
infect
cell
viru
control
uninfect
cell
cell
control
drug
cytotox
control
cell
drug
use
dilut
rang
drug
test
well
includ
test
plate
three
day
infect
viru
control
well
exhibit
cytopatholog
effect
concentr
ec
cytotox
concentr
tc
determin
drug
outlin
doubl
tripl
combin
studi
drug
test
triplic
five
six
concentr
includ
drug
high
concentr
drug
set
approxim
ec
drug
singl
agent
concentr
drug
use
doubl
tripl
combin
viru
provid
tabl
cytotox
doubl
tripl
drug
combin
determin
use
experiment
format
three
separ
experi
use
concentr
rang
outlin
tabl
extent
viral
cytopatholog
well
determin
stain
neutral
red
nr
detail
elsewher
briefli
cell
stain
nr
dilut
mem
determin
cell
viabil
two
hour
later
plate
process
quantif
nr
uptak
viabl
cell
amount
nr
taken
cell
determin
spectrophotometr
ec
tc
synergi
calcul
ec
tc
synergi
calcul
done
describ
previous
briefli
ec
tc
calcul
singl
agent
made
normal
nr
data
well
cell
viru
control
assum
repres
cell
viabil
cell
viabil
respect
normal
data
plot
percent
cell
viabil
versu
compound
concentr
data
point
fit
use
fourparamet
curv
fit
graphpad
prism
graphpad
softwar
la
jolla
ca
deriv
ec
tc
statist
comparison
bestfit
ec
valu
two
curv
perform
prism
use
extra
sumofsquar
f
test
differ
ec
valu
two
curv
pvalu
consid
signific
synergi
calcul
use
macsynergi
ii
softwar
develop
prichard
shipman
modifi
accommod
threedrug
combin
similar
report
previous
describ
approach
theoret
addit
interact
calcul
concentrationrespons
curv
drug
singl
agent
calcul
addit
surfac
subtract
observ
experiment
surfac
reveal
region
deviat
calcul
addit
effect
pure
addit
interact
repres
graphic
area
grey
indic
differ
calcul
addit
effect
synergist
interact
result
greater
inhibit
calcul
inhibit
repres
area
blue
convers
antagon
repres
area
red
synergi
plot
shown
percent
inhibit
expect
calcul
addit
inhibit
present
mean
three
replic
level
confid
elimin
insignific
deviat
addit
surfac
synergi
volum
doubl
tripl
combin
also
calcul
repres
sum
synergi
antagon
across
concentr
combin
synergi
volum
present
quantit
measur
overal
interact
drug
within
combin
determin
cytopath
effect
neutral
red
assay
synergi
volum
mg
ml
doubl
combin
mgml
tripl
combin
consid
strongli
synergist
convers
combin
synergi
volum
mgml
mg
ml
consid
strongli
antagonist
synergi
cytotox
effect
doubl
tripl
drug
combin
calcul
similar
manner
three
nine
independ
experi
conduct
use
ident
dose
rang
amantadin
ribavirin
oseltamivir
carboxyl
viru
experi
use
plate
format
total
observ
condit
data
independ
experi
merg
subject
statist
analysi
use
random
effect
model
raw
data
import
program
r
normal
viru
cell
control
describ
synergi
percent
inhibit
calcul
calcul
synergi
volum
estim
random
effect
model
appli
data
account
variat
replic
measur
within
experi
therefor
model
took
form
given
ij
measur
j
th
replic
experi
b
grand
mean
u
n
e
ij
n
observ
data
independ
model
allow
proper
estim
standard
error
standard
error
use
determin
statist
signific
synergi
volum
inhibitori
quotient
iq
defin
herein
ratio
expect
averag
total
free
proteinbound
plasma
concentr
c
ave
drug
recommend
dosag
ec
c
ave
ec
thu
iq
greater
mean
achiev
total
plasma
concentr
drug
equal
greater
vitro
effect
concentr
higher
iq
translat
greater
predict
efficaci
c
ave
drug
determin
pharmacokinet
model
use
noncompartment
model
progam
winnonlin
recommend
dose
along
pharmacokinet
paramet
use
model
obtain
packag
insert
amantadin
oseltamivir
ribavirin
refer
therein
ribavirin
sinc
plasma
concentr
achiev
steadyst
week
start
dose
c
ave
determin
first
window
base
paramet
expect
c
ave
amantadin
determin
mgml
base
recommend
dosag
mg
twice
daili
treatment
influenza
infect
expect
c
ave
oseltamivir
determin
mgml
base
recommend
dosag
mg
twice
daili
treatment
influenza
infect
expect
c
ave
ribavirin
determin
mgml
day
treatment
base
recommend
dosag
mg
twice
daili
treatment
hepat
c
infect
determin
iq
tripl
combin
amantadin
ribavirin
oseltamivir
carboxyl
test
fix
ratio
combin
wherein
ratio
three
drug
kept
constant
even
total
concentr
drug
vari
ratio
drug
tcad
regimen
base
expect
c
ave
drug
dilut
curv
tcad
regimen
creat
first
prepar
solut
three
drug
c
ave
drug
mg
ml
amantadin
mgml
oseltamivir
carboxyl
mg
ml
ribavirin
serial
dilut
solut
increment
manner
ec
tcad
regimen
fix
dose
combin
determin
ratio
c
ave
express
unit
foldc
ave
suscept
three
influenza
strain
six
antivir
drug
amantadin
rimantadin
oseltamivir
carboxyl
zanamivir
peramivir
ribavirin
singl
agent
determin
measur
inhibit
virusinduc
cpe
mdck
cell
three
strain
oseltamivir
carboxyl
zanamivir
peramivir
ribavirin
produc
concentrationdepend
inhibit
cytopath
effect
data
shown
amantadin
activ
higher
concentr
ec
mgml
mm
tabl
repres
reduct
suscept
compar
publish
valu
wildtyp
viru
rimantadin
produc
inhibit
cytotox
concentr
ec
mgml
mm
ec
valu
six
drug
singl
agent
three
strain
summar
tabl
confirm
three
viru
strain
remain
suscept
oseltamivir
carboxyl
zanamivir
peramivir
ribavirin
result
consist
result
previous
publish
demonstr
contain
mutat
channel
associ
resist
adamantan
remain
suscept
nai
next
assess
synergist
activ
doubl
tripl
combin
amantadin
ribavirin
oseltamivir
carboxyl
rang
concentr
drug
isol
quantit
measur
total
synergi
antagon
drug
combin
express
term
synergi
volum
repres
cumul
synergi
antagon
across
concentr
drug
combin
base
empir
determin
criterion
synergi
volum
mgml
use
lower
confid
interv
three
doubl
combin
addit
tabl
contrast
tcad
regimen
synergist
three
virus
multipl
concentr
three
drug
synergi
occur
mgml
amantadin
mgml
ribavirin
mgml
oseltamivir
carboxyl
tabl
data
show
synergi
tcad
regimen
occur
clinic
achiev
concentr
three
drug
given
expect
averag
plasma
concentr
base
recommend
dose
mgml
amantadin
mgml
ribavirin
mgml
oseltamivir
carboxyl
furthermor
synergi
tcad
regimen
greater
synergi
doubl
combin
test
three
strain
figur
show
synergi
tcad
regiment
function
increas
concentr
amantadin
ribavirin
oseltamivir
carboxyl
third
drug
repres
contribut
drug
synergi
doubl
combin
without
third
drug
data
reveal
addit
drug
third
drug
doubl
combin
result
concentrationdepend
increas
synergi
indic
drug
contribut
synergi
tcad
regimen
importantli
despit
fact
amantadin
signific
antivir
activ
singl
agent
mgml
data
shown
find
amantadin
contribut
activ
tcad
regimen
clinic
achiev
concentr
mgml
statist
analysi
variabl
across
replic
six
experi
viru
reveal
amantadin
made
signific
contribut
synergi
tcad
regimen
concentr
mgml
mgml
respect
compar
doubl
combin
ribavirinoseltamivir
carboxyl
without
amantadin
figur
mgml
amantadin
concentr
statist
signific
greater
synergi
volum
doubl
combin
without
amantadin
trend
toward
increas
synergi
volum
start
mgml
thu
amantadin
contribut
activ
tcad
regimen
concentr
inact
singl
agent
concentr
clinic
achiev
synergi
plot
reveal
extent
synergi
concentr
drug
combin
shown
figur
data
present
contour
plot
region
inhibit
greater
synergi
less
antagon
expect
identifi
subtract
theoret
addit
inhibit
observ
inhibit
synergi
plot
tcad
regimen
show
concentrationdepend
increas
synergi
respect
amantadin
figur
top
plane
highest
concentr
test
mgml
synergi
observ
wide
rang
concentr
ribavirin
oseltamivir
carboxyl
test
lower
concentr
amantadin
synergi
occur
mgml
ribavirin
higher
mgml
oseltamivir
carboxyl
higher
signific
antagon
observ
dose
drug
doubl
combin
tcad
regimen
similar
pattern
synergi
observ
doubl
tripl
combin
antivir
drug
data
shown
one
notabl
consequ
synergi
antivir
activ
drug
combin
enhanc
compar
activ
drug
singl
agent
demonstr
compar
antivir
activ
three
drugsamantadin
ribavirin
oseltamivir
carboxyl
singl
agent
presenc
fix
concentr
second
third
drug
replic
drug
ec
reduc
tripl
combin
compar
ec
singl
agent
indic
drug
activ
lower
concentr
greater
potenc
exampl
ec
amantadin
singl
agent
reduc
combin
mgml
ribavirin
mgml
oseltamivir
carboxyl
ec
ribavirin
singl
agent
reduc
combin
mgml
oseltamivir
carboxyl
mgml
amantadin
ec
oseltamivir
carboxyl
singl
agent
reduc
combin
mgml
ribavirin
mgml
amantadin
tabl
three
drug
reduct
ec
valu
observ
tripl
combin
compar
singl
agent
statist
signific
indic
drug
greater
antivir
potenc
effect
lower
concentr
addit
ec
three
drug
tripl
combin
reduc
compar
ec
doubl
combin
indic
antivir
activ
drug
tripl
combin
enhanc
compar
doubl
combin
importantli
data
present
repres
maximum
reduct
ec
valu
three
drug
due
dynam
rang
assay
abl
obtain
precis
doserespons
curv
drug
fix
concentr
second
third
drug
well
ec
valu
well
concentr
maximum
synergi
occur
higher
concentr
antivir
activ
second
third
drug
contribut
significantli
inhibit
decreas
linear
rang
assay
reduc
accuraci
curvefit
data
shown
comprehens
assess
interact
two
three
drug
combin
requir
evalu
multipl
concentr
drug
order
quantifi
synergi
entir
dose
rang
done
section
also
evalu
interact
doubl
combin
neuraminidas
inhibitor
nai
shown
tabl
synergi
volum
zanamiviroseltamivir
carboxyl
mgml
mgml
mgml
respect
valu
suggest
zanamiviroseltamivir
carboxyl
combin
addit
virus
zanamivirperamivir
combin
synergi
volum
mgml
mgml
mg
ml
respect
indic
addit
moder
antagon
consist
valu
synergi
plot
nai
doubl
combin
reveal
region
antagon
red
area
occur
higher
concentr
zanamivir
mgml
variabl
concentr
second
nai
oseltamivir
peramivir
figur
similar
result
found
two
strain
furthermor
evalu
ec
nai
combin
fix
concentr
second
nai
reveal
antivir
activ
drug
enhanc
combin
second
drug
data
shown
observ
doubl
combin
neuraminidas
inhibitor
synergist
consist
fact
three
drug
known
target
enzym
bind
substrat
bind
pocket
similar
manner
extens
studi
assess
contribut
amantadin
synergi
tcad
regimen
singl
agent
amantadin
activ
virus
concentr
highest
concentr
test
mgml
data
shown
shown
figur
nc
wi
amantadin
contribut
synergi
tcad
regimen
concentrationdepend
manner
synergi
tcad
regimen
presenc
amantadin
greater
synergi
ribavirinoseltamivir
carboxyl
doubl
combin
without
amantadin
increas
synergi
tcad
regimen
observ
mgml
amantadin
nc
mgml
amantadin
wi
signific
evalu
level
dk
howev
amantadin
make
contribut
synergi
tcad
regimen
within
concentr
rang
test
mgml
synergi
tcad
regimen
greater
synergi
ribavirinoseltamivir
carboxyl
doubl
combin
whether
lack
contribut
amantadin
dk
viru
due
specif
subtyp
mutat
combin
remain
determin
howev
note
amantadin
made
contribut
activ
tcad
regimen
dk
ribavirin
oseltamivir
remain
activ
interact
addit
indic
two
three
drug
contribut
activ
tcad
regimen
viru
data
shown
given
larg
percentag
season
influenza
circul
virus
resist
oseltamivir
next
assess
activ
synergi
tcad
regimen
oseltamivirresist
virus
evalu
spectrum
activ
tcad
regimen
determin
whether
oseltamivir
contribut
activ
tcad
regimen
oseltamivirresist
virus
two
oseltamivirresist
virus
use
bear
substitut
na
demonstr
confer
resist
oseltamivir
ms
hi
singl
agent
oseltamivir
carboxyl
antivir
activ
either
viru
mgml
data
shown
synergi
volum
doubl
tripl
combin
amantadin
ribavirin
oseltamivir
determin
virus
data
present
figur
doubl
combin
amantadin
oseltamivir
carboxyl
amantadineribavirin
ribavirin
oseltamivir
carboxyl
addit
figur
seen
virus
tcad
regimen
synergist
synergi
volum
greater
synergi
volum
doubl
combin
drug
make
contribut
synergi
tcad
regimen
oseltamivirresist
virus
figur
importantli
oseltamivir
carboxyl
contribut
synergi
tcad
regimen
start
mgml
ms
mgml
hi
concentr
achiev
clinic
oseltamivir
carboxyl
activ
singl
agent
resist
strain
synergi
plot
tcad
regimen
ms
hi
provid
figur
reveal
increas
synergi
increas
concentr
oseltamivir
carboxyl
highest
concentr
oseltamivir
carboxyl
test
mgml
synergi
occur
wide
concentr
ribavirin
amantadin
lower
concentr
oseltamivir
carboxyl
synergi
occur
higher
concentr
amantadin
mgml
higher
wide
concentr
ribavirin
signific
antagon
detect
concentr
three
drug
also
determin
ec
oseltamivir
carboxyl
singl
agent
doubl
tripl
combin
oseltamivirresist
virus
summar
tabl
ec
oseltamivir
carboxyl
singl
agent
mgml
ms
mgml
hi
repres
reduct
suscept
compar
publish
valu
wildtyp
viru
ec
oseltamivir
carboxyl
reduc
doubl
combin
ribavirin
mgml
amantadin
ms
reduc
respect
hi
howev
tripl
combin
ribavirin
amantadin
concentr
use
doubl
combin
ec
oseltamivir
carboxyl
reduc
ms
hi
tc
amantadin
singl
agent
mgml
wherea
tc
ribavirin
oseltamivir
carboxyl
singl
agent
mgml
tabl
valu
higher
highest
concentr
drug
use
combin
experi
tabl
furthermor
synergi
analysi
doubl
tripl
combin
reveal
synergist
cytotox
doubl
combin
tcad
regimen
within
concentr
rang
test
data
shown
exampl
cell
treat
tcad
regimen
highest
concentr
test
three
drug
use
combin
experi
mgml
amantadin
mgml
ribavirin
mgml
oseltamivir
carboxyl
exhibit
viabil
statist
differ
cell
control
p
determin
student
ttest
figur
one
indic
expect
clinic
antivir
activ
inhibitori
quotient
iq
defin
herein
ratio
averag
total
plasma
concentr
c
ave
effect
inhibitori
concentr
ec
order
predict
effect
tcad
regimen
circul
influenza
strain
clinic
set
calcul
compar
iq
amantadin
ribavirin
oseltamivir
carboxyl
singl
agent
tcad
regimen
suscept
resist
influenza
viral
strain
includ
determin
iq
tcad
regimen
amantadin
ribavirin
oseltamivir
carboxyl
test
fix
ratio
combin
wherein
ratio
three
drug
kept
constant
even
total
concentr
drug
vari
dilut
curv
tcad
regimen
creat
first
prepar
solut
three
drug
c
ave
drug
mgml
amantadin
mgml
ribavirin
mgml
oseltamivir
carboxyl
serial
dilut
solut
halflog
increment
manner
ec
tcad
regimen
determin
ratio
c
ave
express
unit
fold
chang
c
ave
repres
current
circul
strain
use
new
suscept
viru
suscept
amantadin
ribavirin
oseltamivir
carboxyl
amantadineresist
viru
ms
oseltamivirresist
viru
concentrationrespons
curv
amantadin
ribavirin
oseltamivir
carboxyl
tcad
gener
three
virus
ec
iq
summar
tabl
amantadin
effect
inhibit
ms
vitro
result
iq
respect
howev
iq
amantadin
reduc
test
indic
vitro
concentr
repres
achiev
plasma
concentr
recommend
dose
adequ
inhibit
amantadineresist
viru
vitro
iq
repres
reduct
compar
reduct
compar
ms
similarli
oseltamivir
carboxyl
effect
inhibit
vitro
result
iq
respect
ms
iq
similar
amantadin
amantadineresist
viru
iq
oseltamivir
reduc
oseltamivirresist
viru
compar
suscept
virus
iq
ribavirin
uniformli
low
three
virus
hand
iq
tcad
regimen
fix
dose
combin
consist
high
three
virus
vari
suscept
resist
virus
data
suggest
tcad
regimen
may
broad
util
circul
influenza
strain
includ
strain
resist
either
amantadin
oseltamivir
given
virtual
season
strain
resist
amantadin
virtual
current
circul
season
strain
resist
oseltamivir
pharmacolog
rational
develop
tripl
combin
antivir
drug
tcad
compos
amantadin
ribavirin
oseltamivir
least
two
possibl
three
drug
tcad
regimen
activ
virus
number
studi
evalu
doubl
combin
antivir
influenza
infect
vitro
hayden
et
al
test
tripl
combin
two
antivir
human
interferon
howev
report
effect
drug
combin
resist
influenza
virus
recent
smee
et
al
evalu
effect
doubl
combin
amantadin
ribavirin
oseltamivir
amantadineresist
viru
use
studi
author
found
presenc
amantadin
doubl
combin
provid
ad
benefit
second
drug
alon
either
cell
cultur
mous
model
present
studi
examin
efficaci
synergi
tcad
regimen
virus
resist
oseltamivir
amantadin
includ
consist
previou
find
found
strain
suscept
nai
oseltamivir
carboxyl
zanamivir
peramivir
ribavirin
resist
adamantan
amantadin
rimantadin
surprisingli
found
amantadin
singl
agent
retain
partial
activ
virus
tabl
albeit
activ
reduc
compar
suscept
viru
wherea
rimantadin
activ
cytotox
concentr
observ
suggest
phenotyp
test
addit
determin
genotyp
may
necessari
order
fulli
understand
suscept
profil
novel
viru
may
import
implic
guid
choic
antivir
use
combin
strain
interact
oseltamivir
carboxyl
peramivir
zanamivir
doubl
combin
rang
addit
moder
antagonist
indic
activ
drug
enhanc
combin
compar
activ
singl
agent
result
suggest
doubl
combin
nai
may
provid
ad
benefit
drug
singl
agent
given
nai
bind
substrat
bind
pocket
na
use
drug
combin
absenc
enhanc
activ
rais
risk
select
singl
mutat
could
confer
resist
neuraminidas
inhibitor
simultan
inde
crossresist
oseltamivir
zanamivir
result
singl
amino
acid
chang
document
season
influenza
b
virus
occur
background
result
viru
would
resist
approv
antiinfluenza
drug
total
test
activ
synergi
tcad
regimen
six
amantadineresist
virus
includ
three
strain
two
oseltamivirresist
virus
virus
test
studi
come
three
subtyp
caus
signific
morbid
mortal
human
includ
season
avian
pandem
strain
doubl
combin
amantadineoseltamivir
carboxyl
amantadineribavirin
ribavirinoseltamivir
carboxyl
addit
rang
addit
moder
synergist
virus
data
shown
contrast
except
duck
viru
found
tcad
regimen
synergist
clinic
achiev
concentr
three
drug
synergi
tcad
regimen
greater
doubl
antivir
drug
combin
data
suggest
tcad
regimen
may
broadspectrum
antivir
activ
circul
influenza
virus
includ
strain
resist
either
class
antivir
date
influenza
strain
circul
resist
either
adamantan
oseltamivir
thu
expect
suscept
tcad
regimen
current
rapid
diagnost
test
avail
determin
suscept
profil
influenza
virus
real
time
thu
clinician
often
necessari
inform
guid
appropri
antivir
use
avail
broadspectrum
antivir
therapi
would
effect
major
circul
strain
regardless
suscept
would
high
clinic
util
importantli
found
amantadin
oseltamivir
contribut
synergi
tcad
regimen
amantadineresist
oseltamivirresist
virus
contribut
drug
synergi
tcad
regimen
signific
clinic
achiev
concentr
littl
antivir
activ
singl
agent
instanc
comparison
synergi
volum
tcad
regimen
mgml
amantadin
synergi
volum
ribavirin
oseltamivir
carboxyl
doubl
combin
amantadin
reveal
amantadin
contribut
total
synergi
tcad
regimen
respect
similarli
oseltamivirresist
virus
oseltamivir
carboxyl
mgml
contribut
total
synergi
tcad
regimen
ms
hi
respect
thu
three
drug
contribut
synergi
activ
tcad
regimen
amantadineand
oseltamivirresist
virus
activ
amantadin
oseltamivir
restor
context
tcad
regimen
influenza
strain
resist
drug
therebi
maxim
clinic
util
drug
mechan
amantadin
oseltamivir
carboxyl
contribut
synergi
tcad
regimen
resist
strain
unclear
interact
ha
na
surfac
influenza
particl
complex
well
understood
number
studi
demonstr
hana
interact
affect
suscept
amantadin
oseltamivir
respect
furthermor
amantadin
demonstr
exert
antivir
activ
via
interact
ha
higher
concentr
conceiv
result
proteinprotein
interact
ha
na
bind
drug
one
site
may
affect
conform
therefor
affin
anoth
drug
anoth
site
mechan
ribavirin
contribut
synergi
tcad
regimen
also
unclear
ribavirin
document
act
multipl
mechan
affect
viru
replic
host
immun
respons
remain
elucid
mechan
respons
synergi
amantadin
oseltamivir
final
evalu
activ
inhibitori
quotient
iq
tcad
suscept
resist
virus
repres
current
circul
strain
correl
iq
clinic
efficaci
demonstr
influenza
valuabl
construct
rel
rank
iq
differ
antivir
regimen
suscept
resist
virus
order
assess
spectrum
activ
test
season
suscept
viru
amantadineresist
season
oseltamivirresist
viru
tcad
uniformli
activ
three
virus
significantli
high
iq
tabl
suggest
tcad
may
broad
antivir
activ
current
circul
influenza
strain
may
good
efficaci
clinic
set
strain
data
suggest
tripl
combin
antivir
drug
tcad
compos
amantadin
ribavirin
oseltamivir
may
effect
viabl
therapeut
option
treatment
pandem
season
influenza
infect
bodi
data
present
report
valid
tcad
hypothesi
state
given
suscept
resist
circul
influenza
viru
least
two
case
three
drug
tcad
activ
furthermor
tcad
regimen
appear
overcom
baselin
drug
resist
thu
may
repres
highli
activ
antivir
therapi
season
pandem
influenza
safeti
pharmacokinet
distribut
metabol
amantadin
ribavirin
oseltamivir
singl
agent
well
understood
expect
coadministr
three
drug
result
substanti
increas
risk
patient
compar
administr
individu
drug
addit
three
doubl
combin
test
human
without
advers
effect
includ
amantadin
plu
oseltamivir
amantadin
plu
ribavirin
ribavirin
plu
oseltamivir
clinic
trial
assess
efficaci
safeti
tcad
treatment
influenza
initi
provid
import
data
use
tcad
pandem
season
influenza
tabl
concentr
rang
mgml
drug
test
doubl
tripl
combin
differ
influenza
virus
drug
titrat
half
log
figur
synergi
plot
doubl
tripl
combin
amantadin
ribavirin
oseltamivir
carboxyl
replic
determin
neutral
red
assay
mdck
cell
calcul
addit
interact
subtract
experiment
determin
inhibit
reveal
region
synergi
inhibit
expect
antagon
inhibit
expect
valu
deriv
mean
triplic
data
present
confid
experi
repeat
total
six
time
similar
result
blue
area
indic
concentr
drug
synergist
gray
area
indic
concentr
addit
red
area
indic
concentr
antagonist
intens
color
blue
red
correspond
percent
inhibit
expect
figur
viabil
mdck
cell
treat
tcad
regimen
mdck
cell
incub
tcad
regimen
highest
concentr
three
drug
use
synergi
experi
mgml
amantadin
mgml
ribavirin
mgml
oseltamivir
carboxyl
cell
viabil
determin
neutral
red
assay
hour
valu
mean
nine
replic
three
experi
standard
deviat
differ
viabil
tcad
treat
cell
cell
control
statist
signific
p
student
ttest
found
mb
tif
